Lead · METAL · null
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Lead shows clinical signal disease relevance led by Asperger syndrome. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Use Asperger syndrome as the disease frame, then confirm a stable protein accession before cross-source reuse.
Use Asperger syndrome as the disease frame, then confirm a stable protein accession before cross-source reuse.
Lead shows clinical signal disease relevance led by Asperger syndrome. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with Asperger syndrome because it currently carries clinical signal support. Linked drugs include SUCCIMER. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyLead
Review this target as Lead.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Lead as ChEMBL target CHEMBL2364029. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Lead still has a stable protein naming contract across sources.
Jump to Protein ContextUse this block first when you need to confirm why Asperger syndrome is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Lead |
| Target Type | METAL |
| Organism | null |
Reviewable protein naming and mapping context for this target snapshot.
Review this target as Lead.
Open Targets-ready disease context using the current target-indication evidence contract.
Lead shows clinical signal disease relevance led by Asperger syndrome. 5 more disease programs remain visible in the same review block.
Start review with Asperger syndrome because it currently carries clinical signal support. Linked drugs include SUCCIMER. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.